Jackson Creek Investment Advisors LLC Cuts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Jackson Creek Investment Advisors LLC lessened its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 30.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,259 shares of the company’s stock after selling 12,607 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Elanco Animal Health were worth $422,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth approximately $62,510,000. Dimensional Fund Advisors LP raised its holdings in shares of Elanco Animal Health by 33.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company’s stock valued at $224,920,000 after purchasing an additional 3,816,514 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Elanco Animal Health by 2.9% during the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock worth $753,945,000 after purchasing an additional 1,431,665 shares during the last quarter. Wolf Hill Capital Management LP acquired a new position in shares of Elanco Animal Health during the fourth quarter worth $20,683,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Elanco Animal Health by 4.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after buying an additional 852,281 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the subject of a number of recent analyst reports. Piper Sandler decreased their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, July 1st. Barclays decreased their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.

Elanco Animal Health Stock Down 0.8 %

Elanco Animal Health stock opened at $15.02 on Thursday. The company has a market capitalization of $7.42 billion, a P/E ratio of -5.67, a PEG ratio of 1.54 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. Elanco Animal Health Incorporated has a fifty-two week low of $8.52 and a fifty-two week high of $18.80. The stock has a 50-day simple moving average of $13.79 and a 200-day simple moving average of $15.28.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 earnings per share. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.